Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mazyar Shadman, MD
Fred Hutchinson Cancer Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California, United States
- Massachusetts General Hospital (mgh)
Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- University of Rochester Medical Center
Rochester, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 May 2022
- Primary completion
- 12 Apr 2024
- Completion
- 12 Apr 2024
- Last update posted
- 22 Jul 2024
- Registered enrollment
- 20
- Registry id
- NCT05360238
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.